Anaeropharma Science will be presenting its latest research outcomes at the 2017 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards combination approaches of its i-DPS therapy with immune checkpoint inhibitor at the 2017 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 1st to the 5th in Washington D.C.

The first poster is titled “Synergistic anti-tumor efficacy of combination therapy with APS001F, a cytosine deaminase (CD) expressing Bifidobacterium, 5-fluorocytosine (5-FC) and anti-mPD-1 antibody in syngeneic mice model”, which will be presented on Apr. 4th, from 1:00 PM to 5:00 PM, in the session of Clinical Immunotherapy, Viruses, and Bacteria.

PDF download here

The second one is titled “Enhanced anti-tumor effects by a combination approach of interferon-γ producing recombinant Bifidobacterium and anti-mPD-1 antibody in CT26 syngeneic mouse model”, which will be presented on Apr. 3rd, from 1:00 PM to 5:00 PM, in the session of Checkpoints 2: Small-Molecule Inhibitors.

PDF download here

Comments are closed.